Home › Multipel myeloom › North Carolina › Charlotte
Multipel myeloom klinische studies in Charlotte, NC
21 studies voor Multipel myeloom zoeken deelnemers op locaties in en rond Charlotte (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RekruterenFase 3
- Research Site, Charlotte
- Research Site, Charlotte
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RekruterenFase 1
- Levine Cancer Institute, Charlotte
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RekruterenFase 4
- Levine Cancer Institute, Charlotte
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
RekruterenFase 2
- Atrium Health, Charlotte
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
RekruterenFase 3
- Levine Cancer Institute, Charlotte
- Novant Health, Charlotte
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
RekruterenFase 1/2
- Atrium Health Levine Cancer Institute, Charlotte
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RekruterenFase 2
- Atrium Health's Levine Cancer Institute, Charlotte
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
RekruterenFase 3
- Levine Cancer Institute, Charlotte
- Levine Cancer Institute, Charlotte
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RekruterenFase 1/2
- Atrium Health Levine Cancer Institute /ID# 271510, Charlotte
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
RekruterenFase 3
- Novant Health Cancer Institute, Charlotte
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
RekruterenFase 1
- Atrium Health, Levine Cancer Institute, Charlotte
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
RekruterenFase 1/2
- Research Site, Charlotte
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
RekruterenFase 3
- Research Site, Charlotte
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
RekruterenFase 1/2
- Atrium Health Levine Cancer Institute /ID# 276193, Charlotte
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
RekruterenObservatieonderzoekGezonde vrijwilligers welkom
- Atrium Health Levine Cancer, Charlotte
Pre-malignant States to Hematologic Malignancies in Firefighters
RekruterenObservatieonderzoekGezonde vrijwilligers welkom
- Levine Cancer Institute, Charlotte
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RekruterenFase 3
- Levine Cancer Institute, Charlotte
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RekruterenFase 2
- Levine Cancer Institute, Charlotte
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
RekruterenFase 1/2
- Levine Cancer Institute, Charlotte
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
RekruterenFase 3
- GSK Investigational Site, Charlotte
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
RekruterenFase 1
- Levine Cancer Institute, Charlotte
Multipel myeloom studies in andere steden
- New York City, NY60 studies
- Boston, MA42 studies
- Atlanta, GA42 studies
- Houston, TX38 studies
- Durham, NC37 studies
- Nashville, TN32 studies
- Denver, CO27 studies
- Rochester, MN24 studies
- St. Louis, MO24 studies
- Columbus, OH24 studies
- Baldwin Park, CA23 studies
- Edison, NJ22 studies
Andere studies in Charlotte
- Kanker (alle vormen)27 studies
- Borstkanker22 studies
- Niet-kleincellige longkanker19 studies
- Acute myeloïde leukemie16 studies
- Obesitas16 studies
- Overgewicht15 studies
- Colorectale kanker13 studies
- Eierstokkanker12 studies
- Hartfalen11 studies
- Metastatische kanker11 studies
- Plaveiselcelcarcinoom van hoofd en hals10 studies
- COPD9 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.